Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib Plus Chemotherapy in Relapsed/Refractory Ovarian Cancer
NCT03901118Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of chiauranib in ovarian cancer (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 1 year. Started Jul 2019; status: completed.
02
Drugs
chiauranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03901118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901118.